Two Sigma Advisers LP Takes $57,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Two Sigma Advisers LP purchased a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 16,000 shares of the company’s stock, valued at approximately $57,000.

A number of other large investors have also added to or reduced their stakes in the company. New York State Common Retirement Fund lifted its holdings in Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after buying an additional 10,700 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter valued at about $44,000. PKS Advisory Services LLC purchased a new stake in shares of Aquestive Therapeutics during the fourth quarter worth about $63,000. ProShare Advisors LLC increased its position in shares of Aquestive Therapeutics by 79.8% during the fourth quarter. ProShare Advisors LLC now owns 25,232 shares of the company’s stock worth $90,000 after acquiring an additional 11,200 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Aquestive Therapeutics by 16.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock worth $99,000 after acquiring an additional 3,821 shares in the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

AQST has been the subject of a number of analyst reports. Raymond James set a $7.00 price target on Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital cut their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Oppenheimer initiated coverage on shares of Aquestive Therapeutics in a research report on Monday, June 2nd. They set an “outperform” rating and a $7.00 price target for the company. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $10.14.

Aquestive Therapeutics Stock Down 0.3%

Shares of NASDAQ AQST opened at $3.56 on Monday. The stock’s 50 day moving average price is $2.69 and its two-hundred day moving average price is $3.12. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $5.80. The stock has a market capitalization of $353.61 million, a P/E ratio of -7.91 and a beta of 1.94.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. On average, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.